Skip to main content
Fig. 3 | BMC Pediatrics

Fig. 3

From: Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan

Fig. 3

Efficacy responses to IFX treatment over time in Japanese patients with UC. (a) Median change in CAI scores. The open circle represents the median CAI score at Week 30 (overall). (b) CAI-based remission. (c) Median change in PUCAI scores. The open square represents the median PUCAI score at Week 30 (overall). (d) PUCAI-based remission and patients who achieved a decrease in PUCAI score of ≥20 over 30 weeks of IFX treatment among patients who achieved a response after 8 weeks of treatment. CAI Clinical Activity Index, IFX infliximab, PUCAI Pediatric Ulcerative Colitis Activity Index, UC ulcerative colitis

Back to article page

BMC Pediatrics

ISSN: 1471-2431

Contact us